Podcasts
Listen to the latest hemonc news from international experts
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Multiple myeloma in 2026: MRD, BCMA therapies, CAR-T, and the path to cure
This VJHemOnc podcast explores how immunotherapies and MRD-driven approaches are reshaping the management of multiple myeloma and precursor disease. Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses early intervention strategies and presents findings from the CAR-PRISM study (NCT05767359) of cilta-cel in high-risk smoldering myeloma. Kwee Yong, MD, PhD, FRCP, FRCPath, University College London, London, UK, highlights advances in understanding progression in smoldering myeloma.
Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, The Netherlands, reviews frontline quadruplet regimens, combination maintenance, and MRD-driven strategies, including updates from the PERSEUS trial (NCT04483739). Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses BCMA-targeted therapies, including DREAMM-6 (NCT03544281) and REALiTEC-2 (NCT06285318) evaluating belantamab mafodotin and teclistamab in relapsed/refractory multiple myeloma. Finally, Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, explores evolving definitions of cure and the role of sustained MRD negativity in long-term remission.
Date: 22nd May 2026
